C TL (CD8 +) recognize antigenic peptides complexed with MHC class I molecules on the surface of target cells. Cytotoxic T cells play a crucial role in the protective immune response to numerous experimental models of virus infection and disease (1, 2) . There also is strong evidence that HIV-l-specific CTL play a pivotal role in controlling HIV in vivo. Vigorous HIV-l-specific CTL responses have been detected in infected asymptomatic individuals, and these responses subsequently decline with disease progression (3) . Furthermore, recent studies indicated a correlation between the presence of CTL immunity and the ability of some of these individuals to control virus spread and replication and to become long-term survivors of HIV infection (4) (5) (6) .
Conversely, a possible role for virus-specific CTL in HIV-induced immunopathology has also been postulated. Adoptive transfer of a HIV-specific CTL clone to an AIDS patient resulted in the selection for mutant HIV variants and disease progression (7) . In addition, very high viral replication in the presence of a potent CTL response could also lead to T cell-mediated immunopathological damage, as observed in some model infections with noncytopathic viruses (8) .
The identification of naturally processed, class I-presented peptides unique to HIV-infected cells could provide information regarding HIV-related epitopes and the functional role of CTL in HIV infection and disease. To this end, in this study we performed a subtractive analysis of peptides eluted from MHC class I HLA-A2.1 molecules purified from either HIV-l-infected or uninfected cells by microhigh HPLC and mass spectrometry (MS)k Class I-bound peptides arising as a result of HIV infection would be expected to derive from viral proteins but might also derive from endogenous (cellular) proteins. The application of this very sensitive new technology allowed us to identify the Contributions of F. di Marzo Veronese, D. Amott, and V. Bamaba were equivalent and the order of their names should be considered arbitrary.
1Abbreviations used in this paper: ESI-TMS, electrospray-ionization/triple quadruple mass spectrometry; MS, mass spectometry; m/z, charge/mass; RP, reverse phase. most highly represented peptides in the infected cells without biasing the search towards a specific gene product.
Materials and Methods
Cell Lines and Viruses. The EBV-B lymphoblastoid cell line designated AA2 is highly permissive for HIV-1 infection (9) and expresses HLA-A2.1. We chronically infected the AA2 cell line with HIV-1 strain IIIB. The cell line was tested for expression of HIV-1 proteins by p24 antigen capture assay and immunoprecipitation of lysates prepared from metabolically [3SS]cysteinelabeled cells. The antigen capture assay was performed according to the instructions of a commercially available kit from Cellular Products (Buffalo, NY) and revealed specific release of~100 ng of HIV-1 p24/ml in the supernatant of the infected cells. The immunoprecipitation was performed with a serum from a HIV-1-positive subject and unequivocally demonstrated specific and abundant expression of HIV-1 proteins. Individual clones were derived from the bulk-infected cells by limiting dilution and were monitored for viral protein expression by p24 antigen capture assay and by indirect immunofluorescence. One of the clones, showing evidence of uniform and abundant viral envelope expression in all cells by irnmunofluorescence, was designated AA2-IIIB and selected for large scale expansion. JY is an EBV-B lymphoblastoid cell line also expressing HLA-A2.1. Jurkat is a T cell line derived from acute T cell leukemia. Jurkat A2 was derived from Jurkat upon transfection of the HLA-A2.1 gene.
Extraction ofMHC-bound Peptides. Each batch ofpeptides was
the product of a cell pellet from 10 liters of cells containing "~5 • 109 cells. Purification of MHC and elution ofpeptides was carried out according to previously described procedures (10) . Soluble proteins from the cell lysate were passed over GAP-A3 (irrelevant antibody) and BB7.2 (anti-HLA-A2.1) immunoaffinity columns. Peptides were eluted with 0.2N acetic acid, pH 2.7, further acidified with glacial acetic acid to pH 2.1, and collected by centrifugation through a 5-kD filter. The resulting fractions were concentrated by vacuum centrifugation and screened by MS. Those fractions that contained peptides were pooled together. Typically, three preparations from 10-liter cell suspensions were extracted and pooled for analysis. Generation Of CTL Lines. PBMC (4-5 • 106) were incubated in 1KPMI containing 1% human AB serum for 90 min at 37~ and 5% CO2. The nonadherent cells (PBL) were removed and the adherent fraction was pulsed with 100 ~g/ml of synthetic peptide overnight and used as a source of APC. APC were then extensively washed and incubated with 1.5 X I(Y' responding PBL. After 5 d of culture, 10 U/ml rIL-2 (Proleukin, Emeryville, CA) was added and 2 d later, viable cells from each culture were tested in a conventional 6-h cytotoxicity assay. Peptide-specific cultures were stimulated further with peptide-pulsed irradiated (3,000 rad) autologous PHA-T cell blasts used as APC, expanded with rlL-2, and tested for their ability to recognize endogenously synthesized antigen in infected target cells. PBL-derived from random-selected healthy subjects were primed in vitro by weekly restimulation with autologous peptide-pulsed APC and expanded with rlL2. After five to six rounds of restimulation, the cultures were analyzed for peptide-specific CTL activity and those found to be peptide-specific were used for the generation of CTL clones.
Reduction and Carboxyamidation of
Generation of CTL Clones. T cells clones were isolated and maintained as previously described (11) . Briefly, peptide-specific CTL lines were cloned by limiting dilution at 0.3 cells/well into 96-well U-bottom plates in the presence of 0.5 I~g/ml PHA (PHA-P; Wetlcome, Beckenham, UK), 50 U/ml rlL-2, and irradiated, allogeneic feeder cells. After 2-3 wk, cell growth was detected using an inverted microscope and growing cultures were tested for their ability to kill peptide-pulsed SlCr-labeled target cells. Peptide-specific CD8 + CTL clones were then expanded in rIL-2-containing medium and maintained in culture with 2-wk cycles of restimulation with PHA and allogeneic APC.
Results and Discussion
Given the prevalent expression of the class I allele HLA-A2.1 ("-~46% among Caucasians) (12), we undertook a subtractive analysis of peptides extracted from HLA-A2.1 molecules purified from a B cell line that was either uninfected or infected with HIViim in vitro. We carried out our experiments using B cells since the peptides presented by HLA-A2. Figure 1 . Ion chromatograms of peptides extracted from HLA-A2.1 molecules. HLA-A2.1 molecules were purified from lysates of AA2 and AA2-IIIB cells by immunoaffinity chromatography following described procedures (10) . Shown is HPLC fraction 15 of uninfected (A) and HIV-infected (B) AA2 cells, with the mass spectrum (C) of a peptide unique to infected cells. The fractions containing peptides from three preparations were pooled and concentrated by vacuum centrifugation. Peptides were fractionated by HPLC on a 2.1 nma • 3 cm C18 colunm (ABI). A 40-min binary gradient at 200 Ixl/min of 0--60% solvent B was used to elute the peptides, with fractions collected at 1-min intervals. Solvent A was H20 and 0.1% TFA; solvent B was 60% acetonitrile, 30% HzO, 0.085% TFA. Fractions were concentrated and aliquots corresponding to 1.5 • 109 cells analyzed by capillary LC-MS as described previously (10) . A spectrum covering the mass range 300-1,400 was acquired every 1.5 s. Total ion currents were obtained by summing the signal from every mass in each spectrum. The extracted ion currents represent the signal in each spectrum due to ions of a particular m/z. target of HIV, B cell infection by HIV has been observed both in vitro (13, 14) and in vivo (15) . Peptides were analyzed using the technique of capillary HPLC coupled with ESI-TMS (10). Peptides associated with HLA-A2.1 molecules were purified from both control and 100% HIV-l-infected clonal populations of AA2 cells. The extracted peptides were fractionated by RP-HPLC. Aliquots of each fraction were rechromatographed by capillary RP-HPLC, and the resultant fractions were then directly analyzed by ESI-TMS. At every stage of the procedure, samples from control and HIVinfected cells were treated identically. The mass spectra of each HPLC fraction from infected cells were compared, peptide by peptide, to the mass spectra of the corresponding HPLC fraction from control cells. Where peptides appeared to be unique to either sample, adjacent fractions were also examined to determine whether or not the disparity was simply due to a shift in retention time.
An example of this approach is illustrated in Fig. 1 , in which peptides from fraction 15 of control (Fig. 1 A) and HIV-infected ( Fig. 1 B) cells were compared. The bottom panels of Fig. 1, A and B show the total ion chromatograms for each run; mass spectra were recorded every 1.5 s. The upper panels represent the elution ofpeptides with particular charge/mass (m/z) values. Virtually all of the abundant peptide ions identified from the control sample were also present in the sample from HIV-infected cells. Peptides with m/z 458 and 481 are present in both samples in similar proportions and were used as markers. The peptide with m/z 463, which elutes in the interval between these markers, is present in only the sample from infected cells. The summed mass spectra (Fig, 1 C) reveal that this unique peptide is doubly charged and has a nominal molecular mass of 925 daltons.
Application of this method revealed three peptides that appeared only in the samples derived from HIV-infected cells ( Table 1 ). The sequences of these peptides were determined by collision-activated dissociation (CAD) on the triple quadrupole mass spectrometer. Each peptide is nine residues long and exhibits the HLA-A2.1-binding motif (10) . Synthetic versions of peptides 1 and 2 displayed moderate affinity for HLA-A2.1 in an in vitro peptide--binding assay (16) (Table 1) . Protein sequence databases were searched to identify the protein precursors of these peptides. The three peptide sequences were found to occur within a single cellular protein, human vinculin. Vinculin, a cytoskeletal protein, is an essential component of cell-extracellular matrix adhesions involving integrins (focal adhesions) and cell-cell adhesions involving cadherins (adherens junctions) (17) . Peptides 1, 2, and 3 were redesignated according to their corresponding positions in the vinculin protein sequence (18) as Vine(359_367), Vinc(823_831) , and Vinc(983_991), respectively. The third peptide is unusual in that it contains a modified residue at position 3. Reduction and carboxyamidation of this peptide results in a loss of 45 daltons, consistent with the release of an unknown group with a mass of 102 daltons, followed by addition of the 57-dalton accompanying carboxyamidation of one Cys, suggesting that this residue is Cys modified through a disulfide linkage. It is not known whether this modification preceded antigen processing or was introduced during peptide extraction and purification. The third peptide exactly matches residues 983-991 ofvinculin, providing that Cys is assigned to peptide position 3, corresponding to Cys985 in the published sequence (18) , in accord with our interpretation of the CAD data.
Surprisingly, despite readily demonstrable synthesis of HIV proteins in AA2-IIIB cells, our analyses failed to identify HIV-derived peptides in eluates prepared from infected cells, either by subtractive analysis or through a direct search aided by a large panel of synthetic HIV peptides selected for their ability to bind to HLA-A2.1. Peptides that could be derived from HIV proteins in regions that are conserved among many viral strains were synthesized aaad tested for HLA-A2.1 binding using the quantitative, solu- ble M H C assay (16) . A total of 68 peptides, including previously described epitopes, were identified that bound to HLA-A2.1 with various affinities; infected B cell class I preparations were analyzed for the presence of the 36 strongest binding candidates. Searches were based on the retention times of the synthetic peptides. Each synthetic peptide was screened by ESI-TMS to verify its molecular mass and to determine its characteristic charge state. An aliquot of each synthetic peptide was doped into a preparation o f B cell peptides, and the resulting mixture was fractionated by RP-HPLC. Capillary HPLC-ESI-TMS was used to screen each fraction, and the synthetic peptides were identified on the basis of mass, charge state, and their absence in preparations that had not been doped. A hst was thus compiled that located the H P L C fraction in which each HIV peptide was expected to be found, and the HPLC fractions o f infected cell peptides were searched accordingly. For example, a peptide with a molecular weight of 1,012 was found in H P L C fraction 17 in the doped sample; analysis of fraction 17 of the HIV-infected sample revealed no corresponding peptide with the correct mass and charge state. The neighboring fractions were also analyzed for the peptide in case the HPLC separations were not completely congruent. N o match was found in these fractions either. Several possible matches were generated by this method, but in each case the C A D spectrum o f the candidate did not match that o f the synthetic peptide. W h e n searches for each o f the 36 peptides proved unsuccessful, additional searches were initiated for the expanded set o f peptides on the basis of molecular mass alone, but again no positive matches were found for these peptides. One obvious explanation for this result is that HLA-A2.1-associated HIV peptides are ineffciently processed and presented, at least in AA2-IIIB cells, and as a consequence are difficult to detect by ESI-TMS. The possibility remains, however, that the use o f different conditions or cells might allow direct identification o f HIV-derived peptides presented by infected cells. The identification of vinculin-derived peptides uniquely associated with HLA-A2.1 molecules from infected cells suggested that vinculin might be overexpressed as a result of viral infection. To test this hypothesis, we performed dot blots (Fig. 2 A) with a vincuhn ohgonucleotide probe on total cellular P,.NA from AA2 and AA2-IIIB cells. In repeated experiments, strong signals were observed for infected cells, whereas vinculin m R N A expression was faint to undetectable in uninfected cells. Northern blot analysis confirmed that the signal observed for AA2-IIIB cells arose from a single intense band corresponding to the expected size o f vinculin m R N A (data not shown).
[35S]Cysteine metabohc labeling of uninfected and infected cells followed by immunoprecipitation with vincuhn-specific mAbs confirmed overexpression o f vinculin at the protein level as well (data not shown). Dot blot analysis was additionally performed for total R N A from P B M C from HLA-A2.1+, HIV-l-infected subjects in the symptomatic phase o f AIDS, using P B M C from HLA-A2.1 + healthy subjects as controls. Elevated vinculin levels were observed for each HIV + individual tested, indicating that the vinculin over-
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W h e n P B M C were separated into adherent and nonadherent (PBL) fractions and similarly analyzed, increased vincuhn expression was observed mainly in the PBL fraction, comprised mostly o f T and B lymphocytes (Fig. 2 B) . Moreover, flow cytometric analysis by two-color staining of PBL from HIV-l-infected subjects confirmed the increased expression o f endocellular vincuhn in a fraction o f both the B and T cell populations (Fig. 2 C) .
To determine whether vincuhn-derived peptides are immunogenic for CTL responses, two different approaches were followed. In the first approach, we sought to ehcit C T L responses in PBL derived from HIV-1 + patients or healthy donors after a single in vitro stimulation with autologous HIV + patients, or from healthy subjects (C), were incubated with autologous adherent cells that previously were pulsed with 100 I.~g/ml of either Vinc(3sg_3r ) or Vinc(823_831) peptides. After 5 d, 10 U/ml rlL-2 was added and after a further 2 d, the cultures generated from HLA-A2.1 + PBL were individually tested for specific cytotoxicity against peptide-pulsed (10 lag/ml) or untreated HLA-A2. Healthy subjects (C) were negative for HIV, heapatitis B virus, and hepatitis C virus serological markers.
peptide-pulsed adherent monocytes (APC) (Fig. 3) . CTL that lysed target cells pulsed with vinculin peptides were elicited in vitro after a single stimulation from PBL of HLA-A2.1 + patients, but not from PBL of HLA-A2.1-patients or HLA-A2.1 + normal donors, suggesting that CTL from HLA-A2.1 + patients were vincuhn primed in vivo. Moreover, 6 out of 11 long-term CTL lines, expanded from randomly selected vinculin-specific cultures of HIV patients by a second restimulation with peptide-pulsed APC and IL-2, killed not only peptide-sensitized target cells in a class I-restricted manner but also HIV-l-infected AA2 cells (Fig. 4 A) . In the second approach, a protocol for in vitro priming of peptide-specific CTL, generated from PBL of healthy donors, was developed. After five to six rounds of stimulation with autologous peptide-pulsed APC, a peptide-specific CTL response was detectable in cultures from four out of nine healthy subjects tested, indicating that vinculin-specific CTL precusors are present in the normal T cell repertoire. As evident from a typical experiment shown in Fig. 4 B, three representative Vinc(359_367)-specific CTL clones, generated from an in vitro peptideprimed T cell line, lysed both peptide-pulsed HLA-A2.1 + target cells and AA2-IIIB cells. Jurkat cells expressing HLA A2.1, although productively infected with HIV-lmB, did not overexpress vinculin as result of viral infection and were not susceptible to lysis by vincuhn-specific CTL (Fig.  4 /3 ). These results, together with the lack of any obvious homology between the vinculin-derived peptides described here and HIV-derived sequences, suggest that the self-reactive CTL observed among HIV + subjects arise as a consequence of vinculin overexpression and not through HIV/vinculin cross-reactivity. The above findings provide in vivo correlates of our observations of AA2 cells infected with HIV in vitro. Overexpression of vinculin is directly observed in PBL from HIV + patients. Additionally, the finding of primed CTL, specific for the same vinculin peptides recovered from AA2-IIIB cells, in >50% of the HLA-A2.1 +, HIV + patients studied, strongly implies that HLA-A2.1-mediated presentation of vinculin-derived peptides occurs in vivo. Overexpression of cellular proteins upon HIV infection has been described previously by others (19) (20) (21) who have shown that dysregulated expression of cellular proteins may be driven by Tat-mediated transactivation of cellular promoters. Atypical (ectopic) cellular protein expression resulting in the induction of CTL has also been observed in a subpopulation of malignant melanoma patients (22, 23) .
Recently, it has been demonstrated that presentation of self-antigens is induced by the HIV gp120-driven internalization of surface CD4 molecules, leading to enhanced CD4 processing and presentation of MHC class II/CD4 epitopes to autoreactive CD4-specific T helper cells (24) . As described here, the creation of apparently novel class I-vinculin peptide complexes serves to trigger autoreactive CTL in a number of HIV + individuals. These results indicate that HIV infection upregulates the synthesis of vinculin in host cells, allowing the generation of vinculin-derived epitopes in cytosolic processing compartments, and the priming of autoreactive vinculin-specific CTL responses. Moreover, the finding that primary vincuhn-specific CTL responses can be generated in vitro from PBL of healthy subjects, after repeated stimulations with vinculin peptide--pulsed APC, suggests that these self-reactive CTL are present in the peripheral repertoire of normal individuals and become activated upon HIV infection. Self-reactivity in general is currently understood to arise by several mechanisms (25) . In addition to a potentially important role in HIV pathogenesis, the present results obtained for vinculin provide, to our knowledge, the first demonstration of virus-dependent overexpression of a cellular protein implicated in the induction of self-reactive CTL in infected individuals.
